Related Experiment Video
Updated: Aug 17, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Roquin-dependent gene regulation in immune-mediated diseases and future therapies
Timsse Raj1, Arlinda Negraschus2, Vigo Heissmeyer1,2
1Helmholtz Munich, Institute of Molecular Immune Regulation, Feodor-Lynen-Str. 21, 81377 Munich, Germany.
Abstract:
The RNA-binding proteins Roquin-1/2 and Regnase-1 exert essential regulation by controlling pro-inflammatory mRNA expression to prevent autoimmune disease. More recently, inhibition of this post-transcriptional gene regulatory program has been demonstrated to enable enhanced anti-tumor responses by tumor antigen-specific CD8+ T cells. In this review, we describe the functions of these RNA-binding proteins and the phenotypes that arise in association with genetic inhibition or inactivation. We discuss how inducible inactivation of the system reprograms CD4+ and CD8+ T cell fates by changing cell metabolism, activation, differentiation or effector/memory decisions. We furthermore outline what we need to know to precisely modulate this system in order to dampen autoimmune reactions or boost the efficacy of adoptively transferred T cells or chimeric antigen receptor (CAR) T cells in cancer immunotherapies.
Insights
Roquin-1/2 and Regnase-1 RNA-binding proteins control inflammation to prevent autoimmune disease and enhance anti-tumor immunity. Modulating these proteins may improve cancer immunotherapies and dampen autoimmune reactions.
Area of Science:
- Immunology
- Molecular Biology
- Gene Regulation
Background:
- Roquin-1/2 and Regnase-1 are key RNA-binding proteins regulating pro-inflammatory mRNA.
- Their dysregulation is linked to autoimmune diseases.
- Inhibition of this pathway enhances anti-tumor CD8+ T cell responses.
Approach:
- This review details the functions of Roquin-1/2 and Regnase-1.
- It examines phenotypes associated with their genetic inactivation.
- It discusses the reprogramming of T cell fates upon inducible inactivation.
Key Points:
- Inactivating Roquin-1/2 and Regnase-1 reprograms CD4+ and CD8+ T cells.
- Changes involve cell metabolism, activation, differentiation, and effector/memory decisions.
- Precise modulation is crucial for therapeutic applications.
Conclusions:
- Understanding Roquin-1/2/Regnase-1 regulation is vital for treating autoimmune diseases.
- Targeting this system can boost efficacy of T cell-based cancer immunotherapies, including CAR T cells.
More Related Videos
11:50Retroviral Transduction of Helper T Cells as a Genetic Approach to Study Mechanisms Controlling their Differentiation and Function
Published on: November 4, 2016
18:08Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
Published on: December 31, 2007
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Microorganisms in Medicine and Therapeutics
Regulation of Hematopoietic Stem Cells
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Translational Regulation